PROMISING PRACTICES, LESSONS LEARNED

Results from Capability Assessment and Program Measures for ATSH Wave 1 Cohort
Webinar Reminders

1. Everyone is muted.
   • Press *7 to unmute and *6 to re-mute yourself.

2. Remember to chat in questions!

3. Webinar is being recorded and will be sent out via email and posted to the program page.
ATSH Background

- Addiction Treatment Starts Here: Primary Care (ATSH:PC) supports primary care clinics in expanding access to Medications for Addiction Treatment (MAT) for patients with opioid use disorder.

- ATSH:PC has two waves of teams:
  - Wave 1 includes 39 clinics and started in February 2019
  - Wave 2 includes 17 clinics and started in September 2019

- All teams are (informally) assigned to a track:
  - Track 1: Teams that are starting new MAT programs, or are working to put more infrastructure in place
  - Track 2: Teams that are expanding MAT to new sites and/or refining existing programs

ATSH:PC is funded by the California Department of Health Care Services and Cedars-Sinai Community Benefit Giving Office
Capability Assessment
(IMAT-PC)
CAPABILITY ASSESSMENT

Change in IMAT-PC Total Score from Baseline to Midpoint by Team (n=41)
CAPABILITY ASSESSMENT

Average IMAT-PC Scores by Track (N=42 Teams)

- Fully Integrated
- Partially Integrated
- Not Integrated

- Infrastructure
- Clinic Culture & Environment
- Patient Identification & Initiating Care
- Care Delivery & Treatment Response Monitoring
- Care Coordination
- Workforce
- Staff Training & Development
- Total

- Track 1 Baseline (n=23)
- Track 1 Midpoint (n=22)
- Track 2 Baseline (n=19)
- Track 2 Midpoint (n=19)
Program Measures

(NICHQ)
PROGRAM MEASURE – B1 & B2

Total Number of Patients on MAT by Track (n=42 Teams)

- **Jan-Mar'19**: Track 1 Buprenorphine (n=23) - 123, Track 2 Buprenorphine (n=19) - 975
- **Apr-Jun'19**: Track 1 Buprenorphine (n=23) - 184, Track 2 Buprenorphine (n=19) - 1,057
- **Jul-Sep'19**: Track 1 Naltrexone (n=23) - 232, Track 2 Naltrexone (n=19) - 1,187
- **Oct-Dec'19**: Track 1 Naltrexone (n=23) - 278, Track 2 Naltrexone (n=19) - 1,232
Program Measure – C2

Six-Month Retention by Track in Q4 (n=29 Teams)

Track 1 (n=12) - 76%
Track 2 (n=17) - 61%

Note: Retention data is not available or applicable to 13 teams.
ATSH:PC Wave 1 Participant

- Location: Central Valley
- Track 1 team (e.g., early stage in MAT program design and implementation)
- Largest change in capability assessment ratings from baseline to midpoint

Eduardo Villarama, MD, Regional Medical Director
La Clinica de La Raza

ATSH:PC Wave 1 Participant

• Location: East Bay (Northern California)
• Track 2 Team (e.g., focused on refining and expanding MAT)
• Success with improving retention in MAT

Mauricio Lask Psy.D.
Behavioral Medicine Specialist
Family Health Centers of San Diego

ATSH:PC Wave 1 Participant

- Hillcrest site
- Location: San Diego
- Track 2 Team (e.g., focused on refining and expanding MAT)
- Success in expanding MAT to serve more patients

Heather Summers, MSW
Associate Director of Substance Use Disorder Services, Department of Special Populations

Katie Wood
Program Manager, Substance Use Disorder Services
Questions?
We want your feedback!

• Please complete our 2-question poll in the chat box.
• We value your feedback and will use it to help design future ATSH webinars. Thank you!